Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

Mitch Dowsett, Steve R Ebbs, J Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh, Ian E Smith

Research output: Contribution to journalArticlepeer-review

Abstract

To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy.
Original languageEnglish
Pages (from-to)2477-92
Number of pages16
JournalJournal of Clinical Oncology
Volume23
Issue number11
DOIs
Publication statusPublished - 10 Apr 2005

Keywords

  • Aged
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Cell Proliferation
  • Double-Blind Method
  • Female
  • Humans
  • Ki-67 Antigen
  • Middle Aged
  • Neoadjuvant Therapy
  • Nitriles
  • Postmenopause
  • Predictive Value of Tests
  • Receptor, erbB-2
  • Tamoxifen
  • Treatment Outcome
  • Triazoles
  • Tumor Markers, Biological

Fingerprint

Dive into the research topics of 'Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists'. Together they form a unique fingerprint.

Cite this